Sarcoidosis Market to Register Incremental Growth During the Forecast Period (2023-2032), Asserts DelveInsight | Key Players - Pfizer, United Therapeutics, Xentria, aTyr Pharma, Kyorin Pharmaceutical, Novartis, Kinevant Sciences USA - English

DelveInsight's analysts estimate that the sarcoidosis market is expected to show positive growth, mainly attributed to increased prevalence and the expected launch of novel therapies during the forecast period (2023–2032)

LAS VEGAS, Nov. 2, 2023 /PRNewswire/ -- DelveInsight's Sarcoidosis Market Insights report includes a comprehensive understanding of current treatment practices, sarcoidosis emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

Key Takeaways from the Sarcoidosis Market Report

• As per DelveInsight analysis, the sarcoidosis market is expected to grow positively at a significant CAGR during the study period (2019–2032).
• According to DelveInsight's estimates, the US accounts for the highest number of population among the number of patients diagnosed with sarcoidosis among 7MM countries
• Leading sarcoidosis companies such as Pfizer, United Therapeutics, Xentria, Inc., aTyr Pharma, Inc., Kyorin Pharmaceutical Co., Ltd, Novartis, Kinevant Sciences GmbH, and others are developing novel sarcoidosis drugs that can be available in the sarcoidosis market in the coming years.
• Some key therapies for sarcoidosis treatment include Abrocitinib, Inhaled Treprostinil, XTMAB-16, Efzofitimod, CMK389, Namilumab, and others.

Discover which therapies are expected to grab the major sarcoidosis market share @ Sarcoidosis Market Report

Sarcoidosis Overview

Sarcoidosis, an enigmatic systemic condition, is characterized by the formation of immune granulomas in various organs, primarily affecting the lungs and the lymphatic system. Despite its prevalence, the root cause of sarcoidosis remains unidentified, making diagnosis challenging and often delayed due to its wide array of non-specific, unusual, or misleading initial presentations. The clinical expression of sarcoidosis is influenced by various epidemiological and socioeconomic factors. Notably, elderly-onset sarcoidosis is more prevalent in women and often accompanied by a notable decline in overall health and extrapulmonary manifestations, particularly uveitis. The most prevalent diagnostic indicators include bilateral intrathoracic hilar lymphadenopathy or diffuse micronodular pulmonary infiltration observed on chest radiographs, often complemented by a distinctive lymphatic distribution or the characteristic "galaxy sign" on CT scans. Additionally, the disease can manifest in various extra-pulmonary locations, such as the eyes and skin. In cases where less typical clinical or radiological manifestations are predominant, the concurrent presence of these diagnostic signs significantly bolsters diagnostic confidence.

Sarcoidosis Epidemiology Segmentation

The sarcoidosis epidemiology section provides insights into the historical and current sarcoidosis patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. 

The sarcoidosis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Sarcoidosis Diagnosed Prevalent Cases
• Sarcoidosis Gender-specific Cases
• Sarcoidosis Age-specific Cases

Sarcoidosis Treatment Market 

Managing sarcoidosis hinges on two crucial points. Firstly, sarcoidosis often shows spontaneous regression without causing permanent organ damage. Secondly, glucocorticoid use, the primary treatment approach, is linked to severe side effects. Hence, treatment is warranted when symptoms become disabling or when granulomatous inflammation relentlessly progresses, risking life or organ health. The conventional approach to managing patients with significant symptomatic or progressive stage II or III disease, or serious extrapulmonary disease, continues to rely on corticosteroids, according to expert consensus and common clinical practice. There is currently no universally accepted protocol or algorithm for oral corticosteroid therapy. An international consensus statement suggests initiating treatment with prednisone (or its equivalent) at a daily dose of 20 to 40 mg for a duration of four to six weeks.

In cases of stable or improved patient conditions, a slow taper to 5-10 mg per day is advised. If there's no clinical response to steroid therapy after three months, longer courses are unlikely to be effective. Treatment should be continued for a minimum of 12 months before considering tapering. Second- and third-line therapies for pulmonary sarcoidosis, such as methotrexate, azathioprine, leflunomide, biologic agents, and corticotropin gel, are reserved for patients with corticosteroid-resistant disease, intolerable side effects, or those who opt for alternatives to corticosteroids.

To know more about sarcoidosis treatment, visit @ Sarcoidosis Treatment Drugs 

Key Sarcoidosis Therapies and Companies

• Abrocitinib: Pfizer
• Inhaled Treprostinil: United Therapeutics
• XTMAB-16: Xentria, Inc.
• Efzofitimod: aTyr Pharma, Inc./Kyorin Pharmaceutical Co., Ltd
• CMK389: Novartis
• Namilumab: Kinevant Sciences GmbH

Learn more about the FDA-approved drugs for sarcoidosis @ Drugs for Sarcoidosis Treatment 

Sarcoidosis Market Dynamics

Sarcoidosis market dynamics are characterized by a complex interplay of factors that impact the diagnosis, treatment, and research surrounding this rare inflammatory disease. Sarcoidosis is a relatively uncommon condition, and its prevalence varies across different regions, making it challenging for pharmaceutical companies to invest heavily in research and drug development. However, increased awareness, advances in diagnostic techniques, and a growing understanding of the disease's immunological basis have led to a more dynamic landscape. This, in turn, has fostered a sense of optimism for patients and healthcare providers alike. 

Moreover, the development of targeted therapies and the potential for personalized medicine in sarcoidosis treatment are areas of growing interest, promising a more tailored and effective approach to managing this condition. Still, market dynamics in the sarcoidosis arena are heavily influenced by the rarity of the disease, making collaboration among stakeholders, including patient advocacy groups, essential to advancing research and improving patient outcomes. 

However, several factors are impeding the growth of the sarcoidosis market. First and foremost is the disease's rarity, which hampers large-scale investments in research and drug development by pharmaceutical companies. The limited patient pool makes it economically challenging to justify substantial R&D expenditures, potentially slowing down the development of new treatments.

Additionally, the diverse and often unpredictable nature of sarcoidosis, with varying symptoms and disease courses among individuals, poses a substantial challenge in clinical trials and treatment development. This heterogeneity necessitates the identification of specific biomarkers and the development of personalized treatment strategies, which can be time-consuming and costly. Moreover, the lack of awareness and understanding of sarcoidosis among healthcare professionals can lead to misdiagnosis or delayed diagnosis, further complicating patient care. This lack of awareness also affects funding for research and support from public health initiatives.

Scope of the Sarcoidosis Market Report

• Therapeutic Assessment: Sarcoidosis current marketed and emerging therapies
• Sarcoidosis Market Dynamics: Conjoint Analysis of Emerging Sarcoidosis Drugs
• Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Unmet Needs, KOL's views, Analyst's views, Sarcoidosis Market Access and Reimbursement

Discover more about sarcoidosis drugs in development @ Sarcoidosis Clinical Trials

Table of Contents

Related Reports

Sarcoidosis Pipeline

Sarcoidosis Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key sarcoidosis companies, including Relief Therapeutics Holdings, aTyr Pharma, Amgen, Bristol-Myers Squibb, Novartis, Pfizer, United Therapeutics Corporation, among others.

Sarcoidosis Epidemiology

Sarcoidosis Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted sarcoidosis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Pulmonary Sarcoidosis Pipeline

Pulmonary Sarcoidosis Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key pulmonary sarcoidosis companies, including Novartis, aTyr Pharma, Relief Therapeutics, AI Therapeutics, SarcoMed USA, among others.

Pulmonary Sarcoidosis Market

Pulmonary Sarcoidosis Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key pulmonary sarcoidosis companies, including Novartis, aTyr Pharma, Relief Therapeutics, AI Therapeutics, SarcoMed USA, among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us
Shruti Thakur
[email protected]
+1(919)321-6187
www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg

SOURCE DelveInsight Business Research, LLP